Phase II, proof-of-concept trial of VX 661 in combination with ivacaftor in patients with cystic fibrosis who have one copy of the F508del mutation and one copy of the G551D mutation
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2015
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary) ; Tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 11 Jan 2015 Status changed from recruiting to completed, according to a Vertex Pharmaceuticals media release.
- 21 Oct 2013 New trial record
- 17 Oct 2013 Results from this trial are expected in the first quarter of 2014, according to a Vertex Pharmaceuticals media release.